294 related articles for article (PubMed ID: 18989671)
1. Carboplatin dosing in overweight and obese patients with normal renal function, does weight matter?
Ekhart C; Rodenhuis S; Schellens JH; Beijnen JH; Huitema AD
Cancer Chemother Pharmacol; 2009 Jun; 64(1):115-22. PubMed ID: 18989671
[TBL] [Abstract][Full Text] [Related]
2. Flat dosing of carboplatin is justified in adult patients with normal renal function.
Ekhart C; de Jonge ME; Huitema AD; Schellens JH; Rodenhuis S; Beijnen JH
Clin Cancer Res; 2006 Nov; 12(21):6502-8. PubMed ID: 17085665
[TBL] [Abstract][Full Text] [Related]
3. A universal formula based on cystatin C to perform individual dosing of carboplatin in normal weight, underweight, and obese patients.
Schmitt A; Gladieff L; Lansiaux A; Bobin-Dubigeon C; Etienne-Grimaldi MC; Boisdron-Celle M; Serre-Debauvais F; Pinguet F; Floquet A; Billaud E; Le Guellec C; Penel N; Campone M; Largillier R; Capitain O; Fabbro M; Houede N; Medioni J; Bougnoux P; Lochon I; Chatelut E
Clin Cancer Res; 2009 May; 15(10):3633-9. PubMed ID: 19401344
[TBL] [Abstract][Full Text] [Related]
4. Prospective evaluation of carboplatin AUC dosing in patients with a BMI>or=27 or cachexia.
Herrington JD; Tran HT; Riggs MW
Cancer Chemother Pharmacol; 2006 Jan; 57(2):241-7. PubMed ID: 16133538
[TBL] [Abstract][Full Text] [Related]
5. Carboplatin dose calculation in lung cancer patients with low serum creatinine concentrations using CKD-EPI and Cockcroft-Gault with different weight descriptors.
Kaag D
Lung Cancer; 2013 Jan; 79(1):54-8. PubMed ID: 23131495
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of a non cystatin-C-based novel algorithm to calculate individual glomerular filtration rate in cancer patients receiving carboplatin.
Holweger K; Lipp HP; Beijnen JH; Bokemeyer C; Hartmann JT
Cancer Chemother Pharmacol; 2011 Sep; 68(3):693-701. PubMed ID: 21136060
[TBL] [Abstract][Full Text] [Related]
7. Difference of carboplatin clearance estimated by the Cockroft-Gault, Jelliffe, Modified-Jelliffe, Wright or Chatelut formula.
Nagao S; Fujiwara K; Imafuku N; Kagawa R; Kozuka Y; Oda T; Maehata K; Ishikawa H; Koike H; Aotani E; Kohno I
Gynecol Oncol; 2005 Nov; 99(2):327-33. PubMed ID: 16005943
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of predictive formulae for glomerular filtration rate for carboplatin dosing in gynecological malignancies.
de Lemos ML; Hsieh T; Hamata L; Levin A; Swenerton K; Djurdjev O; Vu T; Hu F; Conklin J; Malfair Taylor SC
Gynecol Oncol; 2006 Dec; 103(3):1063-9. PubMed ID: 16875719
[TBL] [Abstract][Full Text] [Related]
9. Prediction of carboplatin clearance calculated by patient characteristics or 24-hour creatinine clearance: a comparison of the performance of three formulae.
Okamoto H; Nagatomo A; Kunitoh H; Kunikane H; Watanabe K
Cancer Chemother Pharmacol; 1998; 42(4):307-12. PubMed ID: 9744776
[TBL] [Abstract][Full Text] [Related]
10. Extremely high exposures in an obese patient receiving high-dose cyclophosphamide, thiotepa and carboplatin.
De Jonge ME; Mathôt RA; Van Dam SM; Beijnen JH; Rodenhuis S
Cancer Chemother Pharmacol; 2002 Sep; 50(3):251-5. PubMed ID: 12203108
[TBL] [Abstract][Full Text] [Related]
11. Population pharmacokinetics of high-dose carboplatin in children and adults.
Lindauer A; Eickhoff C; Kloft C; Jaehde U
Ther Drug Monit; 2010 Apr; 32(2):159-68. PubMed ID: 20110851
[TBL] [Abstract][Full Text] [Related]
12. An analysis of measured and estimated creatinine clearance rates in normal weight, overweight, and obese patients with gynecologic cancers.
Nelson WK; Formica RN; Cooper DL; Schwartz PE; Rutherford TJ
J Oncol Pharm Pract; 2012 Sep; 18(3):323-32. PubMed ID: 22331238
[TBL] [Abstract][Full Text] [Related]
13. [Estimating renal function based on creatinine clearance: application of different formulas and correction for obese patients].
Apperloo JJ; Gerlag PG; Beerenhout CH; Vader HL
Ned Tijdschr Geneeskd; 2007 May; 151(18):1016-23. PubMed ID: 17508688
[TBL] [Abstract][Full Text] [Related]
14. Carboplatin dosing in obese women with ovarian cancer: a Gynecologic Oncology Group study.
Wright JD; Tian C; Mutch DG; Herzog TJ; Nagao S; Fujiwara K; Powell MA
Gynecol Oncol; 2008 Jun; 109(3):353-8. PubMed ID: 18407341
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics of carboplatin administered with lobradimil to pediatric patients with brain tumors.
Warren K; Gervais A; Aikin A; Egorin M; Balis FM
Cancer Chemother Pharmacol; 2004 Sep; 54(3):206-12. PubMed ID: 15156345
[TBL] [Abstract][Full Text] [Related]
16. Impact of various body weights and serum creatinine concentrations on the bias and accuracy of the Cockcroft-Gault equation.
Winter MA; Guhr KN; Berg GM
Pharmacotherapy; 2012 Jul; 32(7):604-12. PubMed ID: 22576791
[TBL] [Abstract][Full Text] [Related]
17. Population pharmacokinetics of carboplatin in children.
Chatelut E; Boddy AV; Peng B; Rubie H; Lavit M; Dezeuze A; Pearson AD; Roché H; Robert A; Newell DR; Canal P
Clin Pharmacol Ther; 1996 Apr; 59(4):436-43. PubMed ID: 8612389
[TBL] [Abstract][Full Text] [Related]
18. Measured versus estimated glomerular filtration rate in the Calvert equation: influence on carboplatin dosing.
Donahue A; McCune JS; Faucette S; Gillenwater HH; Kowalski RJ; Socinski MA; Lindley C
Cancer Chemother Pharmacol; 2001 May; 47(5):373-9. PubMed ID: 11391850
[TBL] [Abstract][Full Text] [Related]
19. The influence of body size descriptors on the estimation of kidney function in normal weight, overweight, obese, and morbidly obese adults.
Park EJ; Pai MP; Dong T; Zhang J; Ko CW; Lawrence J; Crentsil V; Zhang L; Xu NN
Ann Pharmacother; 2012 Mar; 46(3):317-28. PubMed ID: 22395245
[TBL] [Abstract][Full Text] [Related]
20. Comparison of dosing recommendations for antimicrobial drugs based on two methods for assessing kidney function: cockcroft-gault and modification of diet in renal disease.
Golik MV; Lawrence KR
Pharmacotherapy; 2008 Sep; 28(9):1125-32. PubMed ID: 18752383
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
